Continuing Education TxSCO Annual Conference

TxSCO 2022 Annual Conference

Friday, October 21 - Saturday, October 22
JW Marriott Downtown Houston | Houston, TX

Agenda

Friday, October 21

6:30 - 7:15 PM
Welcome Reception

7:15 - 8:45 PM
Welcome, Opening Remarks
Chris Prakash, MD
President Texas Society of Clinical Oncology

Dinner & Panel Discussion: Bringing the Patient Focus Back into Legislation
David E. Gerber, MD
UT Southwestern Medical Center

Nelda Hunter
Budget and Policy Consultant, HillCo Partners

Christian G. Downs, JD, MHA
Executive Director, Association of Community Cancer Centers

Angela Storseth
Director, Government Relations, The US Oncology Network

Saturday, October 22, 2022

8:00 AM
Welcome & Introductions
Chris Prakash, MD
President Texas Society of Clinical Oncology

8:05 AM
Changes in the Treatment Landscape of HER2 Positive Breast Cancer
Virginia Kaklamani, MD, DSc
UT Health San Antonio

8:50 AM
The Evolving Role of Surgery for Renal Cell Carcinoma
Surena Matin, MD
MD Anderson Cancer Center

9:20 AM
CAR T Therapy for Diffuse Large B-Cell Lymphoma
Paolo Strati, MD
MD Anderson Cancer Center

10:05 AM
Networking Break/Resource Center

10:35 AM
Advocating for Medication Access; How Practices Can Navigate White Bagging Mandates and Drug Authorization Restrictions
Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE
Miami Cancer Institute

11:35 PM
Understanding the Impact of Disparities and Social Determinants of Health on Cancer Care
Alti Rahman, MHA/MBA, CSSBB
Oncology Consultants

Susan Sabo-Wagner, MSN, RN, OCN
Oncology Consultants

12:20 PM
Networking Lunch/Resource Center

1:20 PM
Incorporating Value-Based Care into Oncology Practice
Susan Escudier, MD, FACP
Texas Oncology

2:20 PM
Fellows Abstract Competition Award Presentations

Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases
Brian De, MD, MD Anderson Cancer Center

Comprehensive Molecular Profiling in Patients with Advanced Biliary Tract Cancers in a Latinx-Rich Cohort
Vidit Kapoor, MD, University of Texas Health San Antonio Mays Cancer Center

Impact of COVID-19 Pandemic on Colorectal Cancer Screening and Treatment: A Community Hospital-Based Study
Ahmed Abdelhakeem, MD, Baptist Hospitals of Southeast Texas, Department of Internal Medicine

Electronic Frailty Index: A Risk Stratification Tool for Survival and Healthcare Outcomes in Veterans with Colorectal Cancer
Huili Zhu, MD, Department of Medicine, Baylor College of Medicine

Ambulatory 5FU Infusion Pumps:
Munaf Alkadimi, MD, UTHSCSA

3:10 PM
Closing Remarks

Disclosure Information

Boston University School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships with ineligible companies that faculty, planners, authors and anyone who may be in control of content have been mitigated.

Accreditation Statement for Joint Conference

Credit Designation for Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and the Texas Society of Clinical Oncology.

Boston University School of Medicine designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Nurses

Boston University School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity has been provided by Boston University School of Medicine Continuing Nursing Education and jointly provided by the Texas Society of Clinical Oncology.

Contact Hours: 5.75, of which 3.00 is pharmacology credit worthy.

Learning Objectives

At the end of this educational activity, participants should be able to:

Summarize recent advances in the management of various cancers, such as HER2-positive breast cancer, diffuse large B-cell lymphoma, and gastrointestinal malignancies.
Describe clear, brown, and white bagging and the strategies to navigate these insurer-mandated practices for dispensing medications.
Discuss barriers to care for underserved populations, including social determinants of health, and their role in overcoming these barriers.
Define value-based care.
Evaluate how their practice can benefit from participating in value-based care and quality programs, such as the Centers for Medicare & Medicaid Service’s Enhancing Oncology Model.

Planners/Speakers

Name of Faculty or Presenter/Planner	Reported Financial Relationship

Munaf Alkadimi	No relevant financial relationships.
Brian De	No relevant financial relationships.
Susan Escudier, MD, FACP	No relevant financial relationships.
Jorge Garcia, PharmD, MS, MHA, MBA, FACHE	Jorge Garcia, PharmD, MS, MHA, MBA, FACHE, receives Grant research support from Pharmacosmos, is a speaker for FLASCO, MED, ATOPP, ACCC and is on the board of Trustees for ACCC & FLASCO. He does not plan on discussing unlabeled/investigational uses of a commercial product.
Regina Gibson-Burtnick, BBA, CAE	No relevant financial relationships.
Lynette Henshaw, PharmD, CME Reviewer	No relevant financial relationships.
Virginia Kaklamani, MD, DSc	Virginia Kaklamani, MD, DSc, is a speaker for Pfizer and Seagen and is a consultant and speaker for Gilead, AstraZeneca and Daiichi. She does not plan on discussing unlabeled/investigational uses of a commercial product.
Vidit Kapoor, MD	Vidit Kapoor, MD, owns stock in Pfizer. He does not plan on discussing unlabeled/investigational uses of a commercial product.
Surena F. Matin, MD	Surena F. Matin, MD, is an editor for Elsevier, Consultant for Janssen and Taris, speaker for ASCO and Clinical Care options. She does not plan on discussing unlabeled/investigational uses of a commercial product
Anish Meerasahib	No relevant financial relationships.
Sandra Megally	No relevant financial relationships.
Naomi Moeller, Boston University School of Medicine CME/CNE Office	No relevant financial relationships.
Jasmine Patel, PharmD, CME Reviewer	Jasmine Patel, PharmD, is a speaker for AbbVie and was on the Myovant Ad Board.
Sucharu Prakash, MD	Sucharu Prakash, MD, is a speaker for Myriad. He does not plan on discussing unlabeled/investigational uses of a commercial product
Alti Rahman, MHA, MBA, CSSBB	No relevant financial relationships.
Amy Smith, CNE Course Advisor	No relevant financial relationships.
Paolo Strati, MD	Paolo Strati, MD, receives grant research support from AstraZeneca, Sobi, ALX Oncology, and ADC Therapeutics; and is a consultant for Genentech, ADC Therapeutics. He does not plan on discussing unlabeled/investigational uses of a commercial product.
Carmela A. Townsend, DNP, MS, MBA, RN, Lead Nurse Planner, Boston University School of Medicine CME/CNE Office	No relevant financial relationships.
Huili Zhu, MD	No relevant financial relationships.

How to Claim Your CME and CNE Certificate

To earn credit, you must stay for the entire program. After the conference, participants will receive an email with instructions on how to claim credit.

Disclaimer

These materials and all other materials provided in conjunction with continuing medical education activities are intended solely for purposes of supplementing continuing medical education programs for qualified health care professionals. Anyone using the materials assumes full responsibility and all risk for their appropriate use. Trustees of Boston University makes no warranties or representations whatsoever regarding the accuracy, completeness, currentness, noninfringement, merchantability or fitness for a particular purpose of the materials. In no event will trustees of Boston University be liable to anyone for any decision made or action taken in reliance on the materials. In no event should the information in the materials be used as a substitute for professional care. In no event should information in the materials regarding laws, regulations, or legal liability be considered legal advice or used as a substitute for consulting with an attorney.